2013年と、さらに2023年に、第一線の科学者たちが、老化を進める主なプロセスをまとめました。12の老化の特徴(Hallmarks of Aging)のひとつが幹細胞の枯渇です。年を重ねるにつれて幹細胞は数が減り、疲れていくので、体の修復が遅くなります。著者のひとりであるGuido Kroemerが、2024年2月にシンガポールで、この老化の特徴を説明してくれました。
Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045-1053. doi:10.3324/haematol.2021.279189
U.S. Food and Drug Administration. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. 18 December 2024. (“Ryoncil is the first FDA-approved MSC therapy.”)
Turner L. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. Cell Stem Cell. 2021;28(11):1891-1895. doi:10.1016/j.stem.2021.10.008
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. 22 July 2020, updated 9 April 2024.
Caplan AI. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl Med. 2017;6(6):1445-1451. doi:10.1002/sctm.17-0051
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001
Eggenhofer E, Benseler V, Kroemer A, et al., Hoogduijn MJ. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297. doi:10.3389/fimmu.2012.00297 (study in mice)
de Witte SFH, Luk F, Sierra Parraga JM, et al. Immunomodulation by Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. Stem Cells. 2018;36(4):602-615. doi:10.1002/stem.2779
U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. 6 December 2019.
European Medicines Agency. First stem-cell therapy recommended for approval in EU (Holoclar, for limbal stem cell deficiency after eye burns). News release, 19 December 2014.
Kuriyan AE, Albini TA, Townsend JH, et al., Goldberg JL. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N Engl J Med. 2017;376(11):1047-1053. doi:10.1056/NEJMoa1609583
Berkowitz AL, Miller MB, Mir S, et al., Chi JH. Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”. N Engl J Med. 2016;375(2):196-198. doi:10.1056/NEJMc1600188
Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7(9):676-685. doi:10.1002/sctm.17-0282
International Society for Stem Cell Research (ISSCR). The ISSCR Guide to Stem Cell Treatments. isscr.org/resources/patient-guide (accessed October 2026).